Clinical Trials
54 trialsUse of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
The Netherlands Cancer Institute
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Thomas Jefferson University
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
National Cancer Institute (NCI)
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Stereotactic Radiosurgery With Sunitinib for Brain Metastases
University Health Network, Toronto
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Bristol-Myers Squibb
SURE
Dana-Farber Cancer Institute
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
Jonsson Comprehensive Cancer Center
Bevacizumab in Multiple Phase I Combinations
M.D. Anderson Cancer Center
Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia
OHSU Knight Cancer Institute
Erlotinib and Sunitinib in NSCLC
University of Wisconsin, Madison
Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
Amsterdam UMC, location VUmc
A Phase 1b Trial in Patients With Renal Cell Cancer
Eli Lilly and Company
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
National Cancer Institute (NCI)
SunRaSe
Heidelberg University
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
Amgen
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Progen Pharmaceuticals
SU/Rapamycin
Washington University School of Medicine
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
University of Utah
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
M.D. Anderson Cancer Center
Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors
University of Miami
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer
Pfizer
Rad/Sutent
Duke University
Sunitinib Malate, Hormone Ablation and Radiation Therapy in Patients With Prostate Cancer
M.D. Anderson Cancer Center
A Phase I Trial of Bortezomib and Sunitinib
Emory University
Ph I SU011248 + Irinotecan in Treatment of Pts w MG
Duke University
Sunitinib Malate and Bevacizumab in Treating Patients With Kidney Cancer or Advanced Solid Malignancies
National Cancer Institute (NCI)
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
National Cancer Institute (NCI)
Bevacizumab and Sunitinib in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors
National Cancer Institute (NCI)
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
AEterna Zentaris
Sunitinib in Treating Young Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Study Of Sunitinib In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer
Pfizer
Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive
Pfizer
The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients
Leiden University Medical Center
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
M.D. Anderson Cancer Center
Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy
Jonsson Comprehensive Cancer Center
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
AstraZeneca
To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Study Of Sunitinib In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer
Pfizer
A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors
Pfizer
A Safety Study Of Sunitinib In Combination With Pemetrexed In Patients With Advanced Solid Malignancies
Pfizer
Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer
Pfizer
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
Pfizer
A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors
Pfizer
A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Study Of SU011248 In Combination With Paclitaxel/Carboplatin In Patients With Advanced Solid Tumors
Pfizer